Literature DB >> 8222186

Induction of interleukin-8 expression during cardiopulmonary bypass.

R E Kalfin1, R M Engelman, J A Rousou, J E Flack, D W Deaton, D L Kreutzer, D K Das.   

Abstract

BACKGROUND: Patients undergoing cardiopulmonary bypass (CPB) are known to suffer from a postsurgical systemic inflammatory response, the nature of which remains to be fully elucidated. Interleukin-8 (IL-8) is a newly described, powerful leukocyte chemotactic factor known to be generated after stimulation of interleukin-1 (IL-1). As we have previously documented the generation of IL-1 beta after CPB, it followed that IL-8 generation should be measured in a comparable group of patients. METHODS AND
RESULTS: Twenty-two adult patients aged 41 to 81 years undergoing coronary revascularization were studied for measurements of C3a, C5a, IL-1, IL-8, and OH(.). Blood was collected before surgery, after CPB, and at 24, 48, and 72 hours. A significant increase in IL-1 beta and IL-8 was detected in circulating leukocytes with peak levels at 24 hours after bypass. No IL-1 beta or IL-8 antigen was detected at any time in patient plasma. Comparable to interleukin generation, human complement-derived C5a also peaked after 24 hours, whereas C3a was increased dramatically immediately after CPB, followed by a decline at 24 hours and a progressive increase over the next 48 hours.
CONCLUSIONS: The results demonstrated for the first time the presence of cell-associated IL-8 in CPB patients. This suggests that this powerful polymorphonuclear and T-lymphocyte chemotactic factor may be an important element in leukocyte activation and recruitment after CPB.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8222186

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  9 in total

1.  Kinetics of pro-inflammatory cytokines release in cardiac surgery with cardiopulmonary bypass.

Authors:  S Hirai; T Sueda; K Orihashi; M Watari; K Okada
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2001-04

2.  Repertaxin, a novel inhibitor of rat CXCR2 function, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury.

Authors:  Danielle G Souza; Riccardo Bertini; Angelica T Vieira; Fernando Q Cunha; Steve Poole; Marcello Allegretti; Francesco Colotta; Mauro M Teixeira
Journal:  Br J Pharmacol       Date:  2004-08-09       Impact factor: 8.739

Review 3.  Lung inflammatory response syndrome after cardiac-operations and treatment of lornoxicam.

Authors:  Kosmas Tsakiridis; Andreas Mpakas; George Kesisis; Stamatis Arikas; Michael Argyriou; Stavros Siminelakis; Paul Zarogoulidis; Nikolaos Katsikogiannis; Ioanna Kougioumtzi; Theodora Tsiouda; Eirini Sarika; Ioanna Katamoutou; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

4.  Perioperative serum levels of tumour-necrosis-factor alpha (TNF-alpha), IL-1 beta, IL-6, IL-10 and soluble IL-2 receptor in patients undergoing cardiac surgery with cardiopulmonary bypass without and with correction for haemodilution.

Authors:  A Roth-Isigkeit; T V Borstel; M Seyfarth; P Schmucker
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

5.  Peri-operative interventions, but not inflammatory mediators, increase risk of acute kidney injury after cardiac surgery: a prospective cohort study.

Authors:  Catherine J Morgan; Peter J Gill; Simon Lam; Ari R Joffe
Journal:  Intensive Care Med       Date:  2013-02-16       Impact factor: 17.440

6.  Effect of lornoxicam in lung inflammatory response syndrome after operations for cardiac surgery with cardiopulmonary bypass.

Authors:  Kosmas Tsakiridis; Paul Zarogoulidis; Giorgos Vretzkakis; Dimitris Mikroulis; Andreas Mpakas; Georgios Kesisis; Stamatis Arikas; Alexandros Kolettas; Giorgios Moschos; Nikolaos Katsikogiannis; Nikolaos Machairiotis; Theodora Tsiouda; Stavros Siminelakis; Thomas Beleveslis; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

7.  Induction of cell-associated chemokines after endotoxin administration to healthy humans.

Authors:  D P Olszyna; E De Jonge; P E Dekkers; S J van Deventer; T van der Poll
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

8.  Induction of acute-phase reactive substances during open-heart surgery and efficacy of ulinastatin. Inhibiting cytokines and postoperative organ injury.

Authors:  Y Sato; S Ishikawa; A Otaki; T Takahashi; Y Hasegawa; M Suzuki; T Yamagishi; Y Morishita
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2000-07

9.  The role of serum interleukin-8 in hepatic resections.

Authors:  Tomonobu Gion; Akinobu Taketomi; Ken Shirabe; Hirofumi Hasegawa; Takayuki Hamatsu; Yo-Ichi Yamashita; Keishi Sugimachi; Tomoharu Yoshizumi; Yuji Soejima; Mitsuo Shimada; Yoshihiko Maehara
Journal:  Surg Today       Date:  2010-05-23       Impact factor: 2.549

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.